Understanding Polypharmacy in Workers’ Compensation: High-Risk Drug Combinations
In workers’ compensation, injured workers often manage multiple conditions simultaneously, including chronic pain, anxiety, sleep disturbances, and musculoskeletal injuries. Treating these conditions frequently leads to concurrent use of opioids, gabapentinoids (gabapentin, pregabalin), and benzodiazepines.
This combination is widely recognized by the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and clinical researchers as a high-risk drug interaction due to its strong association with overdose and death [1,2].
FDA Black Box Warning
The FDA requires boxed warnings for the combined use of opioids and other central nervous system depressants, including benzodiazepines. These warnings highlight the risk of:
Profound sedation
Respiratory depression
Coma
Death
What Is Polypharmacy and Why It Matters
Polypharmacy is often defined as the use of multiple medications, but the greater concern is when drug combinations increase risk without improving outcomes [3].
In workers’ compensation, polypharmacy often develops incrementally:
An opioid is prescribed for pain
A gabapentinoid is added for neuropathic symptoms
A benzodiazepine is introduced for anxiety or sleep
Each decision may be reasonable independently, but together they create a high-risk pharmacologic profile.
Workers’ compensation patients are particularly vulnerable due to:
Multiple prescribers
Long-term treatment needs
Fragmented care delivery
This creates an environment where risk builds gradually and may go unrecognized [4].
Pharmacologic Mechanisms: Why the Combination Is Dangerous
Although these medications have different mechanisms, they converge on one critical effect: suppression of the central nervous system and respiratory drive.
Opioids: Depress respiratory function via mu-opioid receptors
Benzodiazepines: Enhance GABA-mediated inhibition and reduce respiratory response
Gabapentinoids: Reduce excitatory signaling and contribute to respiratory suppression
When used together, these effects are synergistic rather than additive, meaning the combined impact is greater than the sum of each drug alone.
Evidence shows:
Opioid + gabapentinoid use is associated with increased overdose risk
Adding benzodiazepines further increases risk significantly
Concurrent CNS depressant use is a major driver of fatal overdose [1,5]
Clinical Risk and Impact
The clinical risk associated with concurrent use of opioids, gabapentinoids, and benzodiazepines follows a predictable and dangerous progression driven by cumulative central nervous system depression:
Sedation → reduced awareness
Slowed breathing → hypoxia
Respiratory depression → arrest → death
This progression reflects the combined pharmacologic effect of multiple sedating medications acting on respiratory control. Data consistently show that co-prescribing central nervous system depressants significantly increases overdose risk, and a substantial proportion of opioid-related deaths involve concurrent use of multiple sedating drugs. Despite this, overlapping prescribing remains a persistent issue in complex claims populations, particularly where care is fragmented or prolonged [1,5].
Managing Risk in Workers’ Compensation
Reducing risk does not require undertreatment; it requires intentional, coordinated medication management. Workers’ compensation patients are especially vulnerable due to longer recovery timelines, multiple prescribing providers, and limited centralized oversight.
Effective strategies include:
Clinical oversight: Regular medication reviews, avoidance of high-risk combinations such as opioids and benzodiazepines, and use of the lowest effective doses
Deprescribing when appropriate: Gradual benzodiazepine tapering, opioid dose reduction aligned with guidelines, and reassessment of continued gabapentinoid use
System-level controls: Use of Prescription Drug Monitoring Programs (PDMPs), pharmacist-led medication reconciliation, and Drug Utilization Review (DUR) programs
Patient-focused care: Education on overdose risk, naloxone access, and use of non-pharmacologic therapies such as physical therapy, cognitive behavioral therapy, and sleep hygiene strategies
Together, these approaches help shift care from reactive prescribing to proactive risk management, improving safety while supporting recovery.
Conclusion
The combination of opioids, gabapentinoids, and benzodiazepines represents one of the most significant and preventable safety risks in workers’ compensation care.
The pharmacologic risk is well understood.
The evidence is consistent.
The outcomes are avoidable.
What is needed is better coordination, improved monitoring, and more intentional prescribing decisions across the care continuum.
By Fatima Alukidi
PharmD Candidate
For questions, e-mail pharmd@prodigyrx.com
Citations
1. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm2. U.S. Food and Drug Administration. FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class. Updated September 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class 3. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. (Used with contemporary interpretation in clinical guidance).
https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-017-0621-24. Centers for Disease Control and Prevention. Clinical guidance for opioid prescribing: recommendations and principles. Updated 2023. Accessed May 13, 2026. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/recommendations-and-principles.html5. National Institute on Drug Abuse. Benzodiazepines and opioids. Updated 2024.
https://nida.nih.gov/research-topics/opioids/benzodiazepines-opioids